All In Biotech

Drug Trial Radar · NCT03425279

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

245

Actual

Start

Feb 15, 2018

Primary completion

Jan 8, 2025

Study completion Jan 8, 2025

Sponsor

Lead sponsor
BioAtla, Inc.Industry
Sponsor type
Industry
First posted
Feb 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.

Conditions

  • Undifferentiated Pleomorphic Sarcoma
  • Myxofibrosarcoma

Interventions

  • CAB-AXL-ADCBiological

    Conditionally active biologic anti-AXL antibody drug conjugate

  • PD-1 inhibitorBiological

    PD-1 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Safety ProfileTime frame: Up to 24 months
  2. Phase 1: Safety ProfileTime frame: Up to 24 months
  3. Phase 1 and 2: Safety ProfileTime frame: Up to 24 months
  4. Phase 2: Confirmed overall response rate (ORR) per RECIST v1.1Time frame: Up to 24 months

Locations

40 sites in 3 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • Children's Hospital Los Angeles

    Los Angeles, California

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • Tower Hematology Oncology Medical Group

    Los Angeles, California

  • Precision NextGen Oncology

    Los Angeles, California

  • UCSF Medical Center - Cancer Immunotherapy Clinic (CIC)

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • Sarah Cannon Research Institute at Health One

    Denver, Colorado

  • Children's Research Institute

    Washington D.C., District of Columbia

  • Moffitt Cancer Center

    Tampa, Florida

  • Northwestern University

    Chicago, Illinois

  • Norton Cancer Institute

    Louisville, Kentucky

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri

  • Comprehensive Cancer Center of Nevada

    Las Vegas, Nevada

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Columbia University

    New York, New York

  • Memorial Sloan Kettering

    New York, New York

  • Duke Cancer Institute

    Durham, North Carolina

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina

  • The Christ Hospital

    Cincinnati, Ohio

  • University Hospitals Seidman Cancer Center

    Cleveland, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Abramson Cancer Center at Pennsylvania Hospital

    Philadelphia, Pennsylvania

  • Tennessee Oncology

    Nashville, Tennessee

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee

  • Mary Crowley Cancer Research

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Utah - Huntsman Cancer Institute

    Salt Lake City, Utah

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Prince of Wales Hospital

    Hong Kong, Hong Kong

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Chang Gung Memorial Hospital

    Taoyuan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.